TYK2 Inhibition in Paradoxical Psoriasis

Sponsor
Prof Curdin Conrad
Study ID
NCT06281106
Phase
PHASE2/PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

Paradoxical psoriasis is a side effect of a biological treatment (anti-tumor necrosis factor agent, short called anti-TNF) that is used to treat diseases of the skin, the intestine or the joints. If paradoxical psoriasis occurs, the anti-TNF-treatment often needs to be stopped and so far, no specific treatment for paradoxical psoriasis exists. This research project aims to study whether the efficacy of the drug 'Deucravacitinib' 6mg, a tablet taken by mouth once a day is superior compared to taking a placebo in treating paradoxical psoriasis.

Key Dates

Start date
Jun 20, 2024
Status verified
Mar 2025
Primary completion
Mar 20, 2025
Completion
Mar 20, 2025

Study Design

Enrollment
2 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: 'Deucravacitinib'
    Deucravacitinib 6mg oral intake once daily for 4 weeks
  • Placebo Comparator: 'Placebo'
    Matching Placebo oral intake once daily for 4 weeks

Primary Outcome Measure

Paradoxical Psoriasis Investigator Global Assessment [ Time Frame: At Week 4 ]

Related Studies